LEADER 02669nam 2200553 450 001 9910136278803321 005 20230807211422.0 035 $a(CKB)3710000000586918 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/40785 035 $a(EXLCZ)993710000000586918 100 $a20160208d2015uuuu fy| 0 101 0 $aeng 135 $aurc|#---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAmyloid-beta clearance in Alzheimer's disease$b[electronic resource] /$ftopic editors: Robert A. Marr and Eliezer Masliah 210 $cFrontiers Media SA$d2015 210 1$a[Place of publication not identified] :$cFrontiers Media SA,$d2015. 210 4$dİ2015 215 $a1 online resource (111 pages) $cillustrations; digital, PDF file(s) 225 0 $aFrontiers research topics 225 1 $aFrontiers in aging neuroscience 311 $a2-88919-443-4 320 $aIncludes bibliographical references. 330 3 $aStrong evidence continues to accumulate indicating that amyloid-beta (A?) is a central part of Alzheimer?s disease (AD) pathogenesis in spite of the negative evidence coming from failed clinical trials. Therefore, mechanisms of clearance of A? are of great interest in understanding AD pathogenesis and the development of effective treatments. This topic focuses on the issues related to A? clearance in AD. The topics covered include proteases that degrade A? and their localization, regulation, and functions. This topic also covers issues related to clearance through uptake by glia and through low-density lipoprotein (LDL) receptor mediated mechanisms. Signal transduction related to AD pathology and clearance is also addressed. Finally, immunotherapy and other novel therapeutic approaches are discussed. 410 0$aFrontiers in aging neuroscience. 606 $aAlzheimer's disease 606 $aAlzheimer's disease$xPathogenesis 606 $aAlzheimer's disease$xMolecular aspects 606 $aNeurosciences 610 $aamyloid-beta 610 $aSignal Transduction 610 $aProteases 610 $aLDL receptors 610 $aClearance 610 $aAlzheimer's disease 615 0$aAlzheimer's disease. 615 0$aAlzheimer's disease$xPathogenesis. 615 0$aAlzheimer's disease$xMolecular aspects. 615 0$aNeurosciences. 676 $a616.831 700 $aRobert Marr$4auth$01377631 702 $aEliezer Masliah$4auth 801 2$bUkMaJRU 906 $aBOOK 912 $a9910136278803321 996 $aAmyloid-beta clearance in Alzheimer's disease$93415133 997 $aUNINA LEADER 01905oam 2200541I 450 001 9910702593903321 005 20160114093930.0 035 $a(CKB)5470000002428235 035 $a(OCoLC)897949488 035 $a(OCoLC)970346478 035 $a(EXLCZ)995470000002428235 100 $a20141210j201310 ua 0 101 0 $aeng 135 $aurmn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aGeneralized Fluid System Simulation Program, version 6.0 /$fA.K. Majundar [and three others] 210 1$aHuntsville, Alabama :$cNational Aeronautics and Space Administration, Marshall Space Flight Center,$dOctober 2013. 215 $a1 online resource (xxxv, 315 pages) $cillustrations (some color) +$eappendixes (389 pages) 225 1 $aNASA/TM ;$v2013-217492 300 $aTitle from title screen (viewed July 9, 2014). 300 $a"October 2013." 320 $aIncludes bibliographical references (pages 312-315). 606 $aMass flow rate$2nasat 606 $aFinite volume method$2nasat 606 $aHeat transfer$2nasat 606 $aThermodynamics$2nasat 606 $aFlow velocity$2nasat 606 $aThermodynamic properties$2nasat 606 $aGraphical user interface$2nasat 615 7$aMass flow rate. 615 7$aFinite volume method. 615 7$aHeat transfer. 615 7$aThermodynamics. 615 7$aFlow velocity. 615 7$aThermodynamic properties. 615 7$aGraphical user interface. 700 $aMajumdar$b A. K.$0641165 712 02$aGeorge C. Marshall Space Flight Center, 712 02$aUnited States.$bNational Aeronautics and Space Administration, 801 0$bGPO 801 1$bGPO 801 2$bGPO 906 $aBOOK 912 $a9910702593903321 996 $aGeneralized Fluid System Simulation Program, version 6.0$93451154 997 $aUNINA